News
GLPG
40.45
+0.95%
0.38
BRIEF-Galapagos Announces CHMP Adoption Of Prac’S Recommendation For Jyseleca
Reuters · 11/11 12:17
Galapagos To Present Encouraging Initial Data From FILOSOPHY Real-World Arthritis Study At ACR Convergence 2022
Benzinga · 11/08 21:56
Where Galapagos Stands With Analysts
Benzinga · 11/07 21:43
Galapagos downgraded to market perform at Raymond James on unclear path forward
Seekingalpha · 11/07 15:51
RBC Capital Maintains Sector Perform on Galapagos, Lowers Price Target to $53
Benzinga · 11/07 14:50
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
Benzinga · 11/07 14:25
Morgan Stanley Maintains Equal-Weight on Galapagos, Lowers Price Target to $57
Benzinga · 11/07 14:20
Raymond James Downgrades Galapagos to Market Perform
Benzinga · 11/07 12:26
--RBC Lowers Price Target on Galapagos to $53 From $55, Keeps Sector Perform Rating
--RBC Lowers Price Target on Galapagos to $53 From $55, Keeps Sector Perform Rating
MT Newswires · 11/07 09:41
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
Guiding principles for a sustainable future: Invest in strategic therapeutic areas of oncology and immunologyRebuild and accelerate portfolio of transformational medicines in high unmet medical needsCombine internal with external innovation Capital allocat...
GlobeNewswire · 11/04 20:01
BRIEF-Galapagos Reports Strong Third Quarter 2022 Results
Reuters · 11/03 22:19
Galapagos GAAP EPS of -€0.16, revenue of €410.2M
Seekingalpha · 11/03 20:38
Galapagos Q3 2022 Earnings Preview
Seekingalpha · 11/02 21:35
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Benzinga · 10/31 15:17
Galapagos to host its R&D Update 2022 in New York on 4 November 2022
Mechelen, Belgium; 17 October 2022, 07.30 CET; - Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host its R&D Day 2022 for analysts, investors and financial press on Friday, 4 November 2022. The live event will take place at the Yale Cl...
GlobeNewswire · 10/17 05:30
Expert Ratings for Galapagos
Over the past 3 months, 4 analysts have published their opinion on Galapagos (NASDAQ:GLPG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Benzinga · 10/13 14:05
Morgan Stanley Maintains Equal-Weight on Galapagos, Raises Price Target to $63
Morgan Stanley analyst Matthew Harrison maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and raises the price target from $61 to $63.
Benzinga · 10/13 12:18
--Morgan Stanley Adjusts Galapagos' Price Target to $63 from $61, Keeps Equalweight Rating
--Morgan Stanley Adjusts Galapagos' Price Target to $63 from $61, Keeps Equalweight Rating
MT Newswires · 10/13 10:58
Galapagos to Present Data on Prospective Ulcerative Colitis Treatment at Upcoming Conference
Galapagos to Present Data on Prospective Ulcerative Colitis Treatment at Upcoming Conference
MT Newswires · 10/06 16:32
EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects
Belgian pharmaceutical firm Galapagos (NASDAQ:GLPG) on Monday said t...
Seekingalpha · 10/03 20:56
More
Webull provides a variety of real-time GLPG stock news. You can receive the latest news about Galapagos Nv through multiple platforms. This information may help you make smarter investment decisions.
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.